Ramsay Health Care Ltd (ASX: RHC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Ramsay Health Care Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Ramsay Health Care Ltd (ASX: RHC)
Latest News
Share Market News
5 things to watch on the ASX 200 on Friday
Broker Notes
These ASX 200 shares could rise 20% to 40%
Share Market News
5 things to watch on the ASX 200 on Monday
Broker Notes
Brokers name 3 ASX shares to buy now
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Why Harvey Norman, Macquarie Technology, Ramsay Health Care, and Star are rising
Healthcare Shares
Ramsay Health Care share price falls on profit crunch and dividend cut
Share Market News
5 things to watch on the ASX 200 on Thursday
Cheap Shares
'Attractive recovery play': 2 ASX 200 shares ready to rock after a SHOCKING 2023
Healthcare Shares
What is the outlook for ASX healthcare shares in 2024?
Share Gainers
Here are the top 10 ASX 200 shares today
Dividend Investing
Which ASX 200 healthcare share will pay the best dividend yield in FY24?
Frequently Asked Questions
-
Yes, Ramsay Health Care has historically paid two fully franked dividends a year.
-
Ramsay Health Care generally pays its shareholder dividends in March and September.
-
Ramsay Health Care Ltd listed on the ASX on 24 September 1997.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
11 Mar 2024 | $0.4000 | 100.00% | Interim | 05 Apr 2024 |
06 Sep 2023 | $0.2500 | 100.00% | Final | 29 Sep 2023 |
06 Mar 2023 | $0.5000 | 100.00% | Interim | 30 Mar 2023 |
05 Sep 2022 | $0.4850 | 100.00% | Final | 29 Sep 2022 |
07 Mar 2022 | $0.4850 | 100.00% | Interim | 31 Mar 2022 |
06 Sep 2021 | $1.0300 | 100.00% | Final | 30 Sep 2021 |
08 Mar 2021 | $0.4850 | 100.00% | Interim | 31 Mar 2021 |
05 Mar 2020 | $0.6250 | 100.00% | Interim | 27 Mar 2020 |
05 Sep 2019 | $0.9150 | 100.00% | Final | 30 Sep 2019 |
06 Mar 2019 | $0.6000 | 100.00% | Interim | 29 Mar 2019 |
05 Sep 2018 | $0.8650 | 100.00% | Final | 28 Sep 2018 |
06 Mar 2018 | $0.5750 | 100.00% | Interim | 29 Mar 2018 |
05 Sep 2017 | $0.0000 | 100.00% | Final | 28 Sep 2017 |
07 Mar 2017 | $0.5300 | 100.00% | Interim | 29 Mar 2017 |
06 Sep 2016 | $0.7200 | 100.00% | Final | 29 Sep 2016 |
08 Mar 2016 | $0.4700 | 100.00% | Interim | 30 Mar 2016 |
08 Sep 2014 | $0.5100 | 100.00% | Final | 24 Sep 2014 |
04 Mar 2014 | $0.3400 | 100.00% | Interim | 26 Mar 2014 |
03 Sep 2013 | $0.4150 | 100.00% | Final | 25 Sep 2013 |
04 Mar 2013 | $0.2900 | 100.00% | Interim | 27 Mar 2013 |
05 Mar 2012 | $0.2550 | 100.00% | Interim | 28 Mar 2012 |
02 Sep 2011 | $0.2950 | 100.00% | Final | 26 Sep 2011 |
08 Mar 2011 | $0.2250 | 100.00% | Interim | 28 Mar 2011 |
31 Aug 2010 | $0.2500 | 100.00% | Final | 27 Sep 2010 |
16 Mar 2010 | $0.1850 | 100.00% | Interim | 09 Apr 2010 |
21 Sep 2009 | $0.2150 | 100.00% | Final | 09 Oct 2009 |
20 Mar 2009 | $0.1650 | 100.00% | Interim | 08 Apr 2009 |
25 Sep 2008 | $0.1750 | 100.00% | Final | 15 Oct 2008 |
26 Sep 2007 | $0.1600 | 100.00% | Final | 12 Oct 2007 |
27 Mar 2006 | $0.1050 | 100.00% | Interim | 12 Apr 2006 |
26 Sep 2005 | $0.1150 | 100.00% | Final | 14 Oct 2005 |
16 Apr 2004 | $0.0750 | 100.00% | Interim | 30 Apr 2004 |
RHC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Ramsay Health Care Ltd
Ramsay Health Care Ltd (ASX: RHC) is one of the largest private healthcare providers in the world, with around 500 facilities across 11 countries. Its operations cover Australia, Europe, the UK, and Asia.
As well as private hospitals, Ramsay operates day surgeries, primary care clinics, diagnostic and imaging centres, mental health facilities, pharmacies, and an expanding range of in-home and community care services.
It is the largest private hospital group in Australia, France, and the Scandanavian countries. Its 52.5%-owned subsidiary Ramsay Sante oversees its European operations. Its UK business includes mental health facilities and a range of clinical specialties.
The vast majority of the company's revenue is generated from its Australian and European operations.
RHC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
18 Apr 2024 | $50.58 | $-0.50 | -0.98% | 273,988 | $50.78 | $50.99 | $50.45 |
17 Apr 2024 | $51.08 | $-0.40 | -0.78% | 240,840 | $51.32 | $51.40 | $51.02 |
16 Apr 2024 | $51.48 | $-0.43 | -0.83% | 500,655 | $51.51 | $51.75 | $51.06 |
15 Apr 2024 | $51.91 | $-0.09 | -0.17% | 327,115 | $51.55 | $52.09 | $51.30 |
12 Apr 2024 | $52.00 | $-0.15 | -0.29% | 256,406 | $51.80 | $52.14 | $51.62 |
11 Apr 2024 | $52.15 | $-1.61 | -2.99% | 431,807 | $53.01 | $53.12 | $52.14 |
10 Apr 2024 | $53.76 | $0.25 | 0.47% | 202,764 | $53.99 | $54.33 | $53.68 |
09 Apr 2024 | $53.51 | $-0.78 | -1.44% | 393,321 | $54.24 | $54.49 | $53.51 |
08 Apr 2024 | $54.29 | $0.28 | 0.52% | 284,400 | $54.03 | $54.59 | $53.97 |
05 Apr 2024 | $54.01 | $-0.03 | -0.06% | 383,413 | $53.34 | $54.25 | $52.95 |
04 Apr 2024 | $54.04 | $0.85 | 1.60% | 307,706 | $53.36 | $54.31 | $53.33 |
03 Apr 2024 | $53.19 | $-1.52 | -2.78% | 733,794 | $53.59 | $53.60 | $52.83 |
02 Apr 2024 | $54.71 | $-1.80 | -3.19% | 741,195 | $54.87 | $55.45 | $54.26 |
28 Mar 2024 | $56.51 | $0.24 | 0.43% | 628,205 | $56.48 | $56.67 | $55.79 |
27 Mar 2024 | $56.27 | $1.08 | 1.96% | 563,964 | $55.20 | $56.27 | $55.02 |
26 Mar 2024 | $55.19 | $0.10 | 0.18% | 265,732 | $54.87 | $55.19 | $54.50 |
25 Mar 2024 | $55.09 | $0.09 | 0.16% | 249,525 | $55.00 | $55.33 | $54.60 |
22 Mar 2024 | $55.00 | $0.53 | 0.97% | 532,631 | $54.44 | $55.06 | $54.17 |
21 Mar 2024 | $54.47 | $0.16 | 0.29% | 455,989 | $54.65 | $54.66 | $54.11 |
20 Mar 2024 | $54.31 | $0.08 | 0.15% | 348,675 | $54.23 | $54.40 | $53.77 |
19 Mar 2024 | $54.23 | $-0.07 | -0.13% | 219,570 | $54.12 | $54.30 | $53.40 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
22 Dec 2023 | Claudia Dyckerhoff | Buy | 2,500 | $128,275 |
On-market trade.
|
15 Dec 2023 | Craig McNally | Issued | 64,625 | $3,261,623 |
Issue of securities. 172,129 Performance Rights
|
20 Nov 2023 | Karen Penrose | Buy | 195 | $9,935 |
On-market trade.
|
16 Nov 2023 | David Thodey | Buy | 4,000 | $210,509 |
On-market trade.
|
15 Nov 2023 | Karen Penrose | Buy | 665 | $34,972 |
On-market trade.
|
14 Nov 2023 | Craig McNally | Issued | 7,674 | $391,084 |
Issue of securities. VWAP
|
31 Aug 2023 | Craig McNally | Expiry | 55,563 | $2,858,716 |
As advised by the company. 107,504 Performance Rights, lapsed
|
05 May 2023 | Karen Penrose | Buy | 822 | $49,922 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David Ingle Thodey | Non-Executive DirectorNon-Executive Chairman | Nov 2017 |
Mr Thodey is a business leader focused on innovation, technology, digital transformation and telecommunications, with more than 40 years of experience. In addition to being a Non Executive Director and Lead Independent Director of Ramsay, Mr Thodey is currently Chair of Xero Limited. He is also a member of the Finance Committee at the University of Sydney, Chair of the Great Barrier Reef Foundation and co-chair of the Climate Leaders Coalition. Mr Thodey was previously CEO of Telstra Chair of CSIRO and, prior to that, he was CEO of IBM Australia and New Zealand. Mr Thodey is active in public policy and has led an Independent Review of the Australian Public Service in 2019, chaired a Panel appointed by the NSW Government to lead an independent review of Federal Financial Relations between the Commonwealth and the States in 2020, and led a user audit of the myGov government services digital portal in 2023. From March to December 2020, Mr Thodey was also Deputy Chair of the Federal Government's National COVID-19 Coordination Commission NCC Advisory Board. He is Chair of Governance Committee & Member of People Committee.
|
Ms Catriona Alison Deans | Non-Executive Director | Nov 2018 |
Ms Alison Deans has 25 years' experience building technology enabled businesses involved in media, ecommerce, financial services and health, and across leadership roles as an executive, a director and in venture capital. Ms Deans joined the Board of Ramsay Health Care in November 2018. She is also Chair of Cochlear Limited and a Non Executive Director of Calix Limited and Deputy Pty Ltd. She is also a Venture Partner of Main Sequence Ventures. In her executive career, Ms Deans was previously the CEO of eBay Australia and New Zealand, CEO of eCorp Limited, a publicly listed portfolio of digital businesses, CEO of Hoyts Cinemas and recently CEO of Netus Pty Ltd a technology investment company acquired by Fairfax. She is Chair of People Committee and Member of Governance Committee.
|
Mr Michael Stanley Siddle | Non-Executive Director | May 1975 |
Mr Michael Siddle was appointed as Chairman of the Company on 27 May 2014, having formerly been Deputy Chairman for 17 years and a founding Director. He has built up knowledge of the business and the private hospital industry after starting with the Company in 1968. Mr Siddle has extensive experience in the management of private hospitals and has been involved in Ramsay Health Care's successful through developments, mergers and acquisitions. Mr Siddle is also a Trustee and director of the Paul Ramsay Foundation. During the last three years, Mr Siddle has not served as a director of any listed companies other than Ramsay Health Care Limited. He is Member of People and Governance Committee.
|
Mr Craig Ralph McNally | Chief Executive OfficerManaging Director | Jul 2017 |
Mr Craig McNally was appointed Managing Director and Chief Executive Officer on 3 July 2017, after serving seven years as Chief Operating Officer and 22 years in various roles including Head of Global Strategy and European Operations. Mr McNally is also the Chairman of Ramsay Sante. Mr McNally joined Ramsay in 1988 and is one of the Company's serving executives. During his tenure, he has worked across operational, strategic and financial roles. For the last two decades, Mr McNally has been responsible for the development and implementation of Ramsay's growth including brownfield expansions, international market assessments, mergers and acquisitions and business strategies. He has been at the forefront of all the major acquisitions and deals. His ability to assess the opportunities and risks associated with new business ventures and to evaluate their 'strategic fit', as well as his judgement and insight, has ensured the Company's growth both domestically and internationally. Mr McNally has been a key leader in the development of The Ramsay Way culture and in developing leadership within the global organisation.
|
Ms Helen Kurincic | Non-Executive Director | Mar 2024 |
Ms Kurincic brings executive and board-level experience across the healthcare industry most recently as the Chair of Australian & New Zealand imaging company, Integral Diagnostics (December 2014 - November 2023), and a Non-Executive Director of Australian health insurer, HBF Health (February 2016 - February 2024). Helen has previously held other Executive and Non-Executive healthcare sector roles. Non-Executive Director roles include Estia Health, Victorian Clinical Genetics Service, Sirtex, DCA Group, AMP Capital Investors Domain Principal Group, Melbourne Health and Orygen Youth Mental Health Research Centre. Previous Executive roles include Chief Operating Officer of GenesisCare from its earliest inception in Australia and CEO Heart Care Victoria and CEO of Benetas. Helen has previously also been involved in healthcare government policy reform, including appointments by Health Ministers as Chair of the Professional Programs and Services Committee for the Fourth Community Pharmacy Agreement and Member of the Ministers Implementation Taskforce and Ministers Reference Group for the Long Term Reform of Aged Care. Helen started her healthcare career from the ground up, originally as a nurse at the Royal Melbourne Hospital specialising in intensive care. Helen is currently the Chair of McMillan Shakespeare and a Non-Executive Director of the Carlton Football Club.
|
Ms Karen Lee Collett Penrose | Non-Executive Director | Mar 2020 |
Ms Karen Penrose has had an executive career in leadership and CFO roles, in financial services. She is in financial management, customer outcomes and operating in a changing regulatory environment which stems from 20 years in banking with Commonwealth Bank and HSBC and eight years as a listed company CFO. Ms Penrose has been a full-time director since 2014 and is an experienced committee chair of audit and risk. In addition to being a Non-Executive Director of Ramsay, Ms Penrose also serves as a Director of Ramsay Generale de Sante and as a member of their Audit Committee, and as a Director of Bank of Queensland, Cochlear and Estia Health. She is a member of Chief Executive Women and on the Board of Marshall Investments Pty Limited and Rugby Australia Limited. She is Member of Risk Management Committee.
|
Mr Steven Andrew Sargent | Non-Executive Director | Nov 2021 |
Mr Steven Sargent's executive career included 22 years at General Electric, where he gained multi-industry, international experience leading businesses in industries including healthcare, energy and financial services across the USA, Europe and Asia Pacific. Mr Sargent is currently a Non-Executive Director of Origin Energy Limited and Chair of infection prevention company Nanosonics Limited. His unlisted board activities include Chairman of The Origin Energy Foundation Limited, Origin's philanthropic arm, and Non-Executive Director of The Great Barrier Reef Foundation. He is Chair of Risk Management Committee.
|
Ms Claudia Ricarda Rita Sussmuth Dyckerhoff | Non-Executive Director | Oct 2018 |
Dr Dyckerhoff joined the Ramsay Health Care Board in October 2018, bringing in market growth strategies, business development and operational performance improvement in hospitals. Dr Dyckerhoff has global experience in hospitals and health care across Europe, Asia, and the USA. She joined McKinsey & Company in Switzerland in 1995 and transferred to the USA focusing on supporting health care companies, including pharmaceutical & medical device companies, payor, provider and health systems in Europe and the USA. In 2006, Dr Dyckerhoff transferred to China, was elected Senior Partner in 2010 and supported health care companies as well as governments across Asia. She also led McKinsey's Asia-wide Health Systems and Services Sector. In 2016, when she was nominated to the Board of Hoffmann-La Roche, she stepped down from her role as Senior Partner and took on an external advisor role. Dr Dyckerhoff also supports start-ups in the health care area; she joined the board of the Health Tech company HUMA in April 2021 and the board of QuEST Global in November 2020. She is Member of Risk Management Committee.
|
Mr James Malcolm McMurdo | Non-Executive Director | Sep 2019 |
Mr McMurdo has more than 30 years' finance and banking experience. He has a background in corporate advisory across mergers and acquisitions, strategic advisory and financing with experience across multiple industries including the healthcare sector. He has held senior operating management roles and worked in both the Asia Pacific and European regions. Mr McMurdo is one of the Founding Partners of Privatus Capital Partners, an advisory and merchant banking business. Prior to establishing Privatus, he held senior management roles at Deutsche Bank and was based in Hong Kong. In the time he was at Deutsche Bank, Mr McMurdo was Global Co-Head of Corporate Finance, Head of Corporate and Investment Bank for Asia Pacific and CEO for Australia and New Zealand. He sat on the firm's Global Executive Committee for the Corporate and Investment Bank for four years. Prior to this, Mr McMurdo was a Partner at Goldman Sachs, where he held senior positions in the Investment Banking Division in Australia and Europe.
|
Ms Henrietta Rowe | Company SecretaryGroup General Counsel | Jun 2019 |
-
|
Martyn Roberts | Chief Financial Officer |
-
|
|
Henrietta Rowe | Company SecretaryGroup General Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hsbc Custody Nominees (Australia) Limited | 50,937,056 | 22.23% |
J P Morgan Nominees Australia Pty Limited | 30,982,831 | 13.52% |
Netwealth Investments Limited <Wrap Services A/C> | 23,759,975 | 10.37% |
Paul Ramsay Holdings Pty Limited | 20,713,455 | 9.04% |
Citicorp Nominees Pty Limited | 17,563,256 | 7.66% |
National Nominees Limited | 6,130,398 | 2.67% |
BNP Paribas Noms Pty Ltd <DRP> | 3,771,448 | 1.65% |
Woolwich Investments Pty Ltd <The Siddle Family Trust> | 3,750,000 | 1.64% |
Custodial Services Limited <Beneficiaries Holding A/C> | 2,948,847 | 1.29% |
Argo Investments Limited | 2,023,131 | 0.88% |
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 1,604,263 | 0.70% |
Washington H Soul Pattinson And Company Limited | 1,304,499 | 0.57% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 1,257,589 | 0.55% |
Australian Foundation Investment Company Limited | 1,226,000 | 0.54% |
Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 1,208,579 | 0.53% |
Mutual Trust Pty Ltd | 935,998 | 0.41% |
HSBC Custody Nominees (Australia) Limited Gsco Eca | 883,942 | 0.39% |
Certane Ct Pty Ltd <Ramsay Unallocated Ac> | 880,466 | 0.38% |
Hsbc Custody Nominees (Australia) Limited II | 682,900 | 0.30% |
UBS Nominees Pty Ltd | 661,134 | 0.29% |